A one year audit of patients with venous thromboembolism presenting to a tertiary hospital in Johannesburg, South Africa

Lara Nicole Goldstein a,b,⇑, Ming-Tung Wu b

a Department of Emergency Medical Care, Faculty of Health Sciences, University of Johannesburg, Johannesburg, Gauteng, South Africa
b Division of Emergency Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

A R T I C L E   I N F O

Article history:
Received 26 January 2017
Revised 16 June 2017
Accepted 17 June 2017
Available online 22 September 2017

Keywords:
Venous thromboembolism
Pulmonary embolism
Venous thrombosis
Emergency department
Developing countries

A B S T R A C T

Introduction: Given the growing burden of venous thromboembolism (VTE) worldwide and the paucity of data from the developing world, the aim of this study was to audit the characteristics, risk factors and length of hospital stay of patients with VTE presenting to a tertiary hospital emergency centre in Johannesburg, South Africa.

Methods: The study was a retrospective record review of all patients who presented with VTE to a tertiary academic emergency centre in Johannesburg, South Africa from 1 April 2012 to 30 March 2013.

Results: Venous thromboembolism was identified in 74 patients; 56 (75.7%) with isolated deep vein thrombosis, 13 (17.6%) with pulmonary embolism and five (6.8%) who had a concurrent deep vein thrombosis with pulmonary embolism. The median age of the patients was 40 years old (range 19–90). The female to male ratio was 2:1. HIV infection, tuberculosis and history of immobilisation were the most common risk factors. The median duration of hospital stay was 14 days (range 4–36). A therapeutic International Normalised Ratio at discharge was only reached in 36.5% of patients.

Conclusion: Venous thromboembolism presentation to the emergency centre is not common, but the risks associated with the morbidity and mortality related to it makes it important despite its relative scarcity. The prevalence of HIV infection amongst patients with VTE is concerning – not only related to the frequency of the pathology but also due to HIV not being factored into the common VTE risk stratification scores.

© 2017 African Federation for Emergency Medicine. Publishing services provided by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

African Relevance

- Despite the risks, there is a paucity of venous thromboembolism data in developing countries.
- HIV prevalence is high; HIV infection is not a factor included in the common venous thromboembolism scoring systems.
- Venous thromboembolism guideline changes make outpatient management an option for resource-limited environments.

Introduction

The presentation of patients with venous thromboembolism (VTE), ranging from asymptomatic deep vein thrombosis (DVT) to fatal pulmonary embolism (PE), is commonplace in emergency centres in high-income countries [1,2]. It is also a common cause of morbidity and mortality [3]. However, little data exist regarding the incidence and management of VTE in low- and middle-income countries (LMICs) [4,5]. Some of the conventional risk factors for VTE include increasing age, cancer, obesity, smoking, surgery, immobilisation and hormone therapy [3]. Despite initial controversy, Human Immunodeficiency Virus (HIV) infection is now acknowledged as an independent risk factor for VTE [3,6]. Due to the higher prevalence of HIV infection in LMICs, particularly in sub-Saharan Africa, patients who present with VTE may have very different characteristics than patients who present with VTE in high-income countries [7].

Given the growing burden of VTE worldwide and the paucity of data from LMICs, the aim of this study was to audit the characteristics, risk factors and length of hospital stay of patients with VTE presenting to a tertiary hospital emergency centre.
**Methods**

This study was a retrospective record review of all patients who presented with VTE to a tertiary academic emergency centre in Johannesburg, South Africa from 1 April 2012 to 30 March 2013. The emergency centre has approximately 60,000 patient visits per annum. This research was approved by the Human Research Ethics Committee of the Faculty of Health Sciences of the University of the Witwatersrand [M130607].

Patients presenting with VTE were identified through the emergency centre registers as well as the radiology department records of DVT ultrasound and computed tomography pulmonary angiograms for PE. The files of these patients were then retrieved from the records department and the data captured by a single abstractor according to a structured data collection sheet. Common VTE risk factors (Table 1) were sought within the patient files. As the study was an audit, the abstractor was not blinded to the outcomes. Any conflicting data were discussed and clarified with an emergency physician.

Patients were only included if they had presented to the emergency centre with a complaint that lead to a diagnosis of PE or DVT (i.e. hospital-acquired VTE was not included). Patients were included even if the diagnosis was not made or suspected in the emergency centre.

Patients that were admitted with VTE were given subcutaneous low molecular weight heparin (enoxaparin) and then bridged to oral warfarin.

**Results**

Venous thromboembolism was identified in 74 patients; 56 (75.7%) with isolated DVT and 13 (17.6%) with isolated PE. There were five (6.8%) patients who had a concurrent DVT with PE.

The median age of the patients with VTE was 40 years (range 19–90). Thirty-five patients (47.3%) were below the age of 40 years (Fig. 1). There was no statistically significant difference between the median age of patients with DVT (39 years; range 23–90) compared to the median age of patients with PE (44 years old; range 19–73). 74% of the patients with VTE were Black, 15% Coloured and 11% Caucasian. The female to male ratio was 2:1. Venous thromboembolism risk factors that were identified from the patients' files are summarised in Table 1.

There were 30 HIV positive patients below the age of 50 years (85.7% of all HIV positive patients). Twenty-four (68.6%) of the HIV positive patients were taking highly active antiretroviral therapy. The therapy itself is an independent risk factor for VTE [6]. This, as well as the high prevalence of HIV in South Africa, underscores our concerns about the exclusion of these risk factors in the major VTE scoring systems, such as the Modified Wells Scoring System, the Revised Geneva Scoring System and the Pulmonary Embolism Rule Out Criteria score [10–12]. These scoring systems were not utilised in this study’s emergency centre when the data from this study were collected. However, these scoring systems are frequently used in the South African clinical setting despite lack of validation in our population.

More than half of the HIV infected patients were taking highly active antiretroviral therapy. The therapy itself is an independent risk factor for VTE [6]. This, as well as the high prevalence of HIV in South Africa, underscores our concerns about the exclusion of these risk factors in the major VTE scoring systems, such as the Modified Wells Scoring System, the Revised Geneva Scoring System and the Pulmonary Embolism Rule Out Criteria score [10–12]. These scoring systems were not utilised in this study’s emergency centre when the data from this study were collected. However, these scoring systems are frequently used in the South African clinical setting despite lack of validation in our population.

The modifiable risk factors of smoking and obesity could possibly have been underestimated due to lack of documentation in the patient files. Cheng et al., however, emphasised both of their associations with VTE in their 2013 meta-analysis [13].

As was the procedure in our hospital, the traditional management of patients with VTE requires hospital admission in order for patients to be started on parenteral heparin (either low molecular weight or unfractionated) and then be bridged to an oral vitamin K antagonist (e.g. warfarin) [1]. Patients are usually kept in hospital until their INR is within the therapeutic range, which may take several days [14]. This is echoed in the 2013 Southern African Society of Thrombosis and Haemostasis guidelines [15]. This model led to a median length of stay of two weeks for our patients. Even with this protracted admission, only 36.5% of patients were discharged with an INR in the therapeutic range, and even though a therapeutic INR was obtained, the time in the therapeutic range for warfarin is commonly only 60–68% [16,17]. But there are also costs (monetary and health-related) linked to hospital admission that need to be taken into account. Although data were not collected regarding morbidity related to admission, it is known that hospital admission itself is not without negative sequelae such as nosocomial pneumonia, urinary tract infections and bedsores.

The 2013 Southern African Society of Thrombosis and Haemostasis guidelines were released prior to the registration of the

| Table 1 | Venous thromboembolism risk factors, N = 70* **. |
|-----------------|-----------------|
| VTE Risk Factors | Number of patients (%) |
| HIV Positive | 35 (50.0) |
| Tuberculosis | 21 (30.0) |
| Immobilisation | 17 (24.3) |
| Smoking | 11 (15.7) |
| Active Cancer | 7 (10.0) |
| Post-Partum | 6 (8.6) |
| Recent Surgery | 5 (7.1) |
| Trauma | 5 (7.1) |
| Central venous catheter in affected limb | 3 (4.3) |
| Obesity*** | 3 (4.3) |
| Previous history of VTE | 3 (4.3) |
| Systemic Lupus Erythematosus | 2 (2.9) |

VTE, venous thromboembolism; HIV, human immunodeficiency virus; *, four patients were excluded due to lack of documentation; **, patients may have had more than one risk factor; ***, not always documented in the file.
non-vitamin K oral anticoagulants (NOACs) in South Africa [15]. The advent of NOACs, such as dabigatran, rivaroxaban, apixaban and edoxaban has challenged the treatment paradigm. The 2016 American College of Chest Physicians guidelines now recommend the use of NOACs over vitamin K antagonists as primary therapy [18]. There is also increasing evidence to support outpatient management and direct discharge from the emergency centre for low-risk patients with DVT and/or PE [1,18,19]. The largest of these trials will be completed in August 2017 in the United States [20]. Kline et al. showed that patients preferred the autonomy associated with outpatient management [21]. This may also have a knock-on effect leading to better patient compliance. The ramifications of VTE admission, continued INR monitoring and higher incidence of severe bleeding complications needs to be balanced against the higher costs of utilising the newer, safer NOACs for outpatient treatment. Perhaps all these factors combined are sufficient to justify outpatient management of VTE in South Africa? If feasible and economically viable, this would better answer this question. These data were collected from 2012 to 2013 prior to the implementation of VTE protocols in the emergency centre. The retrospective nature of this audit made missing data a constraint for analysis, e.g. not all patients may have been asked about all possible risk factors. This was a single centre study making wider applicability limited. Without the benefit of electronic health records or a registry to obtain the data, some VTE patients may have been inadvertently excluded. Data regarding morbidity and mortality were not collected.

Venous thromboembolism presentation to the emergency centre is not common, but the risks associated with the morbidity and mortality related to it makes it important despite its relative scarcity. The prevalence of HIV infection amongst patients with VTE is concerning, not only related to the frequency of the pathology but also due to HIV not being factored into the common VTE risk stratification scores.

Conflicts of interest

LG has received honoraria from Bayer Healthcare for speaking on venous thromboembolism. No financial support was given for this study; the authors covered all costs incurred.

Dissemination of results

Results from this study were shared with the management of the Hospital.

Authors’ contributions

LG conceived the original idea. MW collected the data. LG and MW carried out the analysis of the data. LG drafted the manuscript. LG and MW approved the final version that was submitted.

References

[1] Singer AJ, Thode Jr HC, Peacock WF. Admission rates for emergency department patients with venous thromboembolism and estimation of the proportion of low risk pulmonary embolism patients: a US perspective. Clin Exp Emerg Med 2016;3(3):126–31. http://dx.doi.org/10.15441/ceem.15.096.
[2] Yusuf HR, Tsai J, Siddiqi A, Boulet SB, Soucie JM. Emergency Department visits by patients with venous thromboembolism, 1998–2009. J Hospital Admin 2012 Sep;1(1). http://dx.doi.org/10.5430/jha.v1n1p1.
[3] Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombol 2016 Jan;41(1):32–67. http://dx.doi.org/10.1007/s11239- 015-1317-0.
[4] Kamerkar DR, John MJ, Desai SC, Disilva LC, Joglekar SJ. Arrive: a retrospective registry of Indian patients with venous thromboembolism. Indian J Crit Care Med 2016 Mar;20(3):150–8. http://dx.doi.org/10.1007/s12299-015-1317-0.
[5] Duncan A. The case for venous thromboembolism prophylaxis in Africa. East Afr Med J 2009 Dec;86(12 Suppl):S108–9. http://dx.doi.org/10.4314/eamj.v86i12.62921.

[6] Rasmussen LD, Dybdal M, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, et al. HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study. HIV Med 2011 Apr;12(4):202–10. http://dx.doi.org/10.1111/j.1468-1393.2010.00869.x.

[7] The Global HIV/AIDS Epidemic. HIV.gov <https://www.aids.gov/hiv-aids-basics/hiv-aids-101/global-statistics/> [accessed 25.01.2016].

[8] Awolesi D, Naidoo M, Cassimjee MH. The profile and frequency of known risk factors or comorbidities for deep vein thrombosis in an urban district hospital in KwaZulu-Natal. S Afr J HIV Med 2016;17(1):a425. http://dx.doi.org/10.4102/sajhivmed.v17i1.425.

[9] Veller M, Pillai J. Lower limb venous thrombosis. Contin Med Educ 2009;27(7):306.

[10] Douma RA, Gibson NS, Gerdes VE, Büller HR, Wells PS, Perrier A. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Thromb Haemost 2009 Jan;101(1):197–200. http://dx.doi.org/10.1160/TH08-07-0444.

[11] Klok FA, Mos IC, Nijkeuter M, Righini M, Perrier A, Le Gal G, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med 2008 Oct 27;168(19):2131–6. http://dx.doi.org/10.1001/archinte.168.19.2131.

[12] Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost 2004 Aug;2(8):1247–55. http://dx.doi.org/10.1111/j.1538-7836.2004.00750.x.

[13] Cheng Y-J, Liu Z-H, Yao F-J, Zeng W-T, Zheng D-D, et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med 2013;10(9):e1001515. http://dx.doi.org/10.1371/journal.pmed.1001515.

[14] Kahlon P, Nabi S, Arshad A, Jabbar A, Haythem A. Warfarin dosing and time required to reach therapeutic international normalized ratio in patients with hypercoagulable conditions. Turk J Haematol 2016 Dec;1;33(4):299–303. http://dx.doi.org/10.4274/tjh.2015.0271.

[15] Jacobson BF, Louw S, Büller H, Mer M, de Jong PR, Rowji P, et al. Venous thromboembolism: prophylactic and therapeutic practice guideline. S Afr Med J 2013 Feb 15;103(4):261–7. http://dx.doi.org/10.7196/SAMJ.6706.

[16] Caldeira D, Cruz I, Morgado G, Stuart B, Gomes C, Martins C, et al. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res Notes 2014 Dec;7(1):801. http://dx.doi.org/10.1186/1756-0500-7-801.

[17] Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, et al. Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. Am Heart J 2015 Jul;170(1):141–8. http://dx.doi.org/10.1016/j.ahj.2015.03.017. 148.e1.

[18] Kearon C, Akh EA, Ornellas J, Biais A, Jimenez D, Bounnameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. CHEST 2016;149(2):315–52. http://dx.doi.org/10.1016/j.chest.2015.11.026.

[19] Beam DM, Kahler ZP, Kline JA. Immediate discharge and home treatment with rivaroxaban of low-risk venous thromboembolism diagnosed in two U.S. Emergency Departments: a one-year preplanned analysis. Acad Emerg Med 2015 Jul;22(7):788–95. http://dx.doi.org/10.1111/acem.12711.

[20] Kabrhel C. Outpatient treatment of pulmonary embolism and deep vein thrombosis: impact of a new protocol on emergency department efficiency and patient safety. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 – [25 January 2017]. Available from: <https://clinicaltrials.gov/ct2/show/record/NCT02533287> Identifier: NCT02532387.

[21] Kline JA, Kahler ZP, Beam DM. Outpatient treatment of low-risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance. Patient Prefer Adherence 2016 Apr;15(10):561–9. http://dx.doi.org/10.2147/PPA.S104486.